SLE and Arthralgia- The role of musculoskeletal ultrasound (US) and fluorescence optical Imaging (FOI) Xiralite® in the diagnostic of inflammatory joint and tendon involvement in SLE

SLE and Arthralgia- The role of musculoskeletal ultrasound (US) and fluorescence optical Imaging (FOI) Xiralite® in the diagnostic of inflammatory joint and tendon involvement in SLE - SLE & A

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023484

Enrollment

118

Registered

2021-02-05

Start date

2019-04-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

Group 1: Musculosceletal ultrasound of predefined joints and fluorescence optical imaging (FOI) of both Hands at baseline visit (only one visit)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -Diagnosis of systemic lupus erythematosus. -Arthralgia at recruitment time. -No visible joint swelling detectable. -No alternations in therapy regime (e.g. corticosteroid treatment) four weeks prior to recruitment. -Examination with FOI is medically indicated

Exclusion criteria

Exclusion criteria: -Diagnosis of rheumatic disease other than SLE. -Visible, clinically detectable joint swelling at recruitment. -Gout or bacterial Arthritis. -Psychiatric disease disabling full understanding of protocol, consent form and patient information form

Design outcomes

Primary

Measure	Time frame
The aim of the study is to detect pre/-subclinical inflammatory joint and tendon involvement in SLE patients with arthralgia, i.e. without clinical Arthritis (no clinical joint swelling) using musculosceletal US and FOI via Xiralite®. We aim to define US and FOI findings according to international standards using EULAR/OMERACT definition, to compare the findings of these two modalities (US vs. FOI), as well to compare US and FOI findings to clinical characteristics/parameters such as joint pain, pain scores, morning stiffness, functionally scores and to the main disease activity scores SLEDAI and BILAG.	—

Measure

Time frame

The aim of the study is to detect pre/-subclinical inflammatory joint and tendon involvement in SLE patients with arthralgia, i.e. without clinical Arthritis (no clinical joint swelling) using musculosceletal US and FOI via Xiralite®. We aim to define US and FOI findings according to international standards using EULAR/OMERACT definition, to compare the findings of these two modalities (US vs. FOI), as well to compare US and FOI findings to clinical characteristics/parameters such as joint pain, pain scores, morning stiffness, functionally scores and to the main disease activity scores SLEDAI and BILAG.

—

Secondary

Measure	Time frame
US and FOI should be examined for their inter- and intra-reader reliability.	—

Countries

Germany

Contacts

Public ContactSarah Ohrndorf

Med. Klinik mit SP Rheumatologie und Klin. Immunologie, Charité-Universitätsmedizin Berlin

sarah.ohrndorf@charite.de+49(0)30450513247

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026